As part of Myriad Genetics, Inc.?s (the ?Company?s?) ongoing succession planning process, Paul J. Diaz, the Company?s President and Chief Executive Officer, announced on February 24, 2025 that he will step down from those positions, and resign from the Company?s Board of Directors (the ?Board?), on April 30, 2025 (the ?Effective Date?). Mr. Diaz is stepping down to join private equity firm, Cressey & Company, as a Managing Partner but will continue to serve the Company as a consultant for another year. Mr. Diaz?
resignation is not due to any disagreement with the Company on any matter relating to the Company?s operations, policies or practices. Having engaged in a robust succession planning process, the Board appointed Samraat S. Raha, the Company's Chief Operating Officer, to succeed Mr. Diaz as its President and Chief Executive Officer on the Effective Date. Since joining the Company, Mr. Raha has played an integral role in shaping the Company?s long-term growth strategy, while delivering new perspectives and expertise to advance the Company?s business initiatives, operational excellence and profitability.
In connection with Mr. Raha?s appointment, the Board also appointed Mr. Raha to the Board to serve as a Class II director with a term expiring at the Company?s 2025 Annual Meeting of Stockholders as of the Effective Date to fill the vacancy on the Board that will be created by Mr. Diaz? resignation. Mr. Raha will assume the duties of the Company?s principal executive officer for Securities and Exchange Commission reporting purposes as of the Effective Date.
Mr. Raha, 52, has served as Chief Operating Officer of the Company since December 2023. Prior to joining the Company, Mr. Raha served as Senior Vice President and President, Diagnostics and Genomics Group, of Agilent Technologies, Inc. (?Agilent?) from April 2018 to December 2023. From May 2017 to April 2018, Mr. Raha served as Agilent's Senior Vice President, Strategy and Corporate Development.
From July 2013 to January 2017, he served as Vice President, Global Marketing for Illumina, Inc., and from 2008 to 2012, he served as Vice President and General Manager, Genomics Assays /NextGen qPCR for Life Technologies, Inc. Mr. Raha graduated from the University of California, Berkeley, with a degree in molecular and cell biology and received his MBA from Santa Clara University. On February 24, 2025, the Board also appointed Mark S. Verratti, the Company?s current Chief Commercial Officer, as its Chief Operating Officer as of the Effective Date to succeed Mr. Raha in this position. Mr. Verratti, 56, has served as Chief Commercial Officer of the Company since April 2022.
He previously served as President, Mental Health or President, Myriad Neuroscience from August 2017 to April 2022, and as President of Myriad Autoimmune from May 2020 until the sale of the Myriad Autoimmune business in September 2021. Prior to his appointment as President, Myriad Neuroscience, he served as SVP, Chief Sales and Business Development Officer at Assurex Health since January 2016. Mr. Verratti also held senior leadership positions worldwide with Cyberonics (now known as LivaNova) from 2005-2016, and earlier with Forest Pharmaceuticals where he led commercial teams with revenues approaching $500 million dollars.
Mr. Verratti received a B.S. in Life Sciences with a minor in Physiology from The Pennsylvania State University.
